
Early Detection, Diagnosis, and Treatment of ATTR
There is no charge to attend this program but you must create an account/register to receive the log in information and claim credit. Please click on the register/take course to sign up. Any questions, please reach out to [email protected] or 617-358-5005.
The live webinar is open to all specialties. The program will focus on the following key areas:
- Early Recognition and Diagnosis: Identifying signs and symptoms of ATTR and addressing barriers to timely diagnosis and patient management.
- Multimodality Imaging: Exploring the role of cardiac MRI, echocardiography, and other imaging tools in diagnosing ATTR-CM.
- Treatment Options: Reviewing FDA-approved therapies and discussing promising emerging treatments.
Target Audience
This program is designed for a broad audience of clinicians involved in the care and treatment of patients with amyloidosis, including general cardiologists, neurologists, hematologists, heart failure specialists, primary care as well as nurses in these areas.
Learning Objectives
Following participation in this webinar, participants will be able to:
- Identify key clinical signs and red flags associated with ATTR that warrant further evaluation.
- Describe the recommended diagnostic pathways for confirming a diagnosis of ATTR, including the appropriate use of imaging, lab testing and genetic screening.
- Discuss current FDA-approved therapies for ATTR, including indications, mechanism of action and considerations for clinical use.
- Effectively make a timely diagnosis and initiate appropriate treatment for patients with ATTR
Moderator
Omar Siddiqi, MD, Clinical Associate Professor, Boston University Chobanian & Avedisian School of Medicine (Course Director)
Speakers
Ahmad Masri, MD, Director of Cardiac Amyloidosis Center at OHSU
Nitasha Sarswat, MD, Assistant Professor, Department of Cardiology at the University of Chicago
Jill Waldron, MSN, GNP, MS at the University of Utah Cardiovascular Center.
CCE Program Manager: Naomi Moeller
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Amyloidosis Research Consortium (ARC). Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Contact Hours: 1.50 of which TBD are eligible for pharmacology credit
Available Credit
- 1.50 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 ANCC
- 1.50 Participation

Facebook
X
LinkedIn
Forward